The global subdermal contraceptive implants market size is expected to reach USD 1.74 billion by 2030, registering a CAGR of 7.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Introduction of several modern contraceptives in the market, growing awareness about various birth control methods, and high per capita income are some of the key factors driving the market for subdermal implants for birth control.
According to the Guttmacher Institute, in 2014, approximately 20 million women needed publicly funded contraceptive services. According to CDC, in 2017, nearly 46.9 million women in the U.S. were using at least one method of contraception. Subdermal implant is a long-term birth control option for women. Subdermal implants for contraception are in the form of polymer capsules or rods placed under the skin. The progestational hormone is released at a slow and stable rate, providing effective contraception for 1-5 years.
Publicly funded family planning services help women avoid or plan pregnancies. In 2012, the South Carolina Department of Health and Human Services (SCDHHS) revised the cost associated with Medicaid payment policy for immediate postpartum insertion of Long-Acting Reversible Contraception (LARC). Under this new reimbursement policy, providers are allowed to bill for the insertion procedure and the cost of an IUD or an implant, in addition to the Diagnosis Related Group (DRG) by using J-codes with a family planning modifier.
Implants are the most widely used contraceptive methods by women in sub-Saharan Africa owing to public-private partnerships between manufacturers, donors, governments, and international agencies, which helps lower commodity cost and increase product availability. Contraceptive usage has increased in South Africa, Malawi, and Rwanda. According to PLOS.org, in Malawi, the use of the Long-acting Reversible Contraception (LARC) method reached 10.21% in urban areas in 2016 and 9.66% in rural areas. In 2012, an initiative called Family Planning 2020 (FP2020) was launched to give 120 million women access to modern contraceptive methods by 2020.
Request a free sample copy or view report summary: Subdermal Contraceptive Implants Market Report
North America held the maximum share in the market for subdermal implants for contraception in 2023. This can be attributed to growing number of unwanted pregnancies, increased government initiatives in favor of contraception, and rising unmet needs
Strong economic growth in countries such as China, India, and Singapore, increasing awareness about contraceptives and STIs, and rising disposable income are expected to boost the Asia Pacific market in the coming years
Rapid population growth is a major concern in sub-Saharan African countries; the region’s population growth is projected to account for more than half of the global population growth by 2050. This could have a positive impact on the uptake of subdermal implants for birth control
Grand View Research has segmented the global subdermal contraceptive implants market based on product, distribution channel, and region:
Subdermal Contraceptive Implants Product Outlook: (Revenue, USD Million, 2018 - 2030)
Etonogestrel Implant
Levonorgestrel Implant
Subdermal Contraceptive Implants Distribution Channel Outlook: (Revenue, USD Million, 2018 - 2030)
Hospital
Gynecology Clinics
Community Health Care Centres
Others
Subdermal Contraceptive Implants Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
KSA
UAE
Kuwait
List Of Key Players Subdermal Contraceptive Implants Market
Bayer AG
Merck & Co. Inc.
Shanghai Dahua Pharmaceutical Co., Ltd.
"The quality of research they have done for us has been excellent..."